AP281A - Sulphate derivatives of galactan extracted from klebsiella - Google Patents

Sulphate derivatives of galactan extracted from klebsiella Download PDF

Info

Publication number: AP281A
Authority: AP; ARIPO
Prior art keywords: galactan; sulphate; klebsiella; derivative; sulphate derivative
Prior art date: 1989-12-04

Application number

APAP/P/1990/000229A

Other languages

English (en)

Other versions

AP9000229A0 (en

Inventor

Pierre Smets

Rene Zalisz

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-04

Filing date

1990-11-27

Publication date

1993-08-08

1990-11-27 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1991-01-31 Publication of AP9000229A0 publication Critical patent/AP9000229A0/xx

1993-08-08 Application granted granted Critical

1993-08-08 Publication of AP281A publication Critical patent/AP281A/en

Links

150000003467 sulfuric acid derivatives Chemical class 0.000 title claims description 28
241000588748 Klebsiella Species 0.000 title claims description 23
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 7
229910021653 sulphate ion Inorganic materials 0.000 claims abstract description 7
238000000034 method Methods 0.000 claims description 15
230000007935 neutral effect Effects 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
238000004587 chromatography analysis Methods 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
150000002632 lipids Chemical class 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
241000588747 Klebsiella pneumoniae Species 0.000 claims description 6
239000012153 distilled water Substances 0.000 claims description 6
238000001914 filtration Methods 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
150000001450 anions Chemical class 0.000 claims description 4
238000000502 dialysis Methods 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
238000005903 acid hydrolysis reaction Methods 0.000 claims description 3
229930182830 galactose Natural products 0.000 claims description 3
230000000717 retained effect Effects 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 2
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
244000005700 microbiome Species 0.000 claims description 2
239000012429 reaction media Substances 0.000 claims description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 27
239000000047 product Substances 0.000 description 24
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 5
102000016387 Pancreatic elastase Human genes 0.000 description 5
108010067372 Pancreatic elastase Proteins 0.000 description 5
230000000694 effects Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000000203 mixture Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
102100022712 Alpha-1-antitrypsin Human genes 0.000 description 3
101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 3
101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
238000003501 co-culture Methods 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229940057948 magnesium stearate Drugs 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000006140 methanolysis reaction Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229960003082 galactose Drugs 0.000 description 2
150000002256 galaktoses Chemical class 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
238000005497 microtitration Methods 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
XQMVBICWFFHDNN-UHFFFAOYSA-N 5-amino-4-chloro-2-phenylpyridazin-3-one;(2-ethoxy-3,3-dimethyl-2h-1-benzofuran-5-yl) methanesulfonate Chemical compound O=C1C(Cl)=C(N)C=NN1C1=CC=CC=C1.C1=C(OS(C)(=O)=O)C=C2C(C)(C)C(OCC)OC2=C1 XQMVBICWFFHDNN-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010002961 Aplasia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000919811 Collyria Species 0.000 description 1
AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical group OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010056740 Genital discharge Diseases 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
VPBCWHDJJAEBGL-UHFFFAOYSA-N piperidin-1-ium-1-sulfonate Chemical compound OS(=O)(=O)N1CCCCC1 VPBCWHDJJAEBGL-UHFFFAOYSA-N 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0036—Galactans; Derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

APAP/P/1990/000229A 1989-12-04 1990-11-27 Sulphate derivatives of galactan extracted from klebsiella AP281A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8915972A FR2655267B1 (fr)	1989-12-04	1989-12-04	Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.

Publications (2)

Publication Number	Publication Date
AP9000229A0 AP9000229A0 (en)	1991-01-31
AP281A true AP281A (en)	1993-08-08

Family

ID=9388107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1990/000229A AP281A (en)	1989-12-04	1990-11-27	Sulphate derivatives of galactan extracted from klebsiella

Country Status (15)

Country	Link
US (1)	US5182378A (de)
EP (1)	EP0433127A3 (de)
JP (1)	JPH04108801A (de)
KR (1)	KR910011878A (de)
CN (1)	CN1062171A (de)
AP (1)	AP281A (de)
AU (1)	AU642933B2 (de)
CA (1)	CA2031320A1 (de)
FR (1)	FR2655267B1 (de)
HU (1)	HUT57236A (de)
IE (1)	IE904342A1 (de)
OA (1)	OA09899A (de)
PT (1)	PT96060A (de)
RU (1)	RU2028381C1 (de)
ZA (1)	ZA909385B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103467625B (zh) *	2013-09-10	2015-08-19	南京海兰琪生物科技有限公司	一种琼胶半乳聚糖硫酸酯的制备方法
NL2011862C2 (en) *	2013-11-29	2015-06-01	Univ Delft Tech	MICROBIAL LINEAR POLYSACCHARIDES.
JP7723394B2 (ja) *	2022-03-31	2025-08-14	協和ファーマケミカル株式会社	植物由来有機分子触媒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3856943A (en) *	1971-06-23	1974-12-24	Upjohn Co	Compositions and process
US3892729A (en) *	1971-06-23	1975-07-01	Upjohn Co	1{40 (Beta-hydroxyethyl)-1{40 -demethyl clindamycin 2-phosphates
FR2543145B1 (fr) *	1983-03-24	1986-10-17	Sanofi Sa	Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
FR2574429B1 (fr) *	1984-12-06	1987-12-11	Roussel Uclaf	Acylglycannes extraits de klebsiella, leur procede d'obtention, leur application a titre de medicaments et les compositions les renfermant
FR2584728B1 (fr) *	1985-07-12	1987-11-20	Choay Sa	Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US4739046A (en) *	1985-08-19	1988-04-19	Luzio Nicholas R Di	Soluble phosphorylated glucan
DE3601136A1 (de) *	1986-01-16	1987-07-23	Max Planck Gesellschaft	Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
EP0240098A3 (de) *	1986-04-04	1989-05-10	Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo	Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
FR2598434B1 (fr) *	1986-05-12	1988-09-16	Pf Medicament	Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
EP0285357A3 (de) *	1987-03-31	1989-10-25	Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo	Bekämpfung von Retroviren
IT1205042B (it) *	1987-05-28	1989-03-10	Crinos Industria Farmaco	Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
IT1217458B (it) *	1988-05-02	1990-03-22	Crinos Ind Farmacoriologica S	Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
US5017565A (en) *	1989-04-20	1991-05-21	Lange Iii Louis G	Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
US5032401A (en) *	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
FR2659351B1 (fr) *	1990-03-08	1994-12-02	Pf Medicament	Compose polysaccharidique delipide, procede de preparation, compositions en comprenant.

1989
- 1989-12-04 FR FR8915972A patent/FR2655267B1/fr not_active Expired - Fee Related
1990
- 1990-11-22 ZA ZA909385A patent/ZA909385B/xx unknown
- 1990-11-27 AP APAP/P/1990/000229A patent/AP281A/en active
- 1990-12-03 KR KR1019900019782A patent/KR910011878A/ko not_active Withdrawn
- 1990-12-03 PT PT96060A patent/PT96060A/pt not_active Application Discontinuation
- 1990-12-03 IE IE434290A patent/IE904342A1/en unknown
- 1990-12-03 CA CA002031320A patent/CA2031320A1/fr not_active Abandoned
- 1990-12-03 EP EP19900403427 patent/EP0433127A3/fr not_active Withdrawn
- 1990-12-03 AU AU67664/90A patent/AU642933B2/en not_active Ceased
- 1990-12-03 RU SU904831773A patent/RU2028381C1/ru active
- 1990-12-03 HU HU908032A patent/HUT57236A/hu unknown
- 1990-12-03 JP JP2403423A patent/JPH04108801A/ja not_active Withdrawn
- 1990-12-04 OA OA59910A patent/OA09899A/fr unknown
- 1990-12-04 US US07/622,719 patent/US5182378A/en not_active Expired - Fee Related
- 1990-12-04 CN CN90109783A patent/CN1062171A/zh active Pending

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number	Publication date
HU908032D0 (en)	1991-06-28
RU2028381C1 (ru)	1995-02-09
EP0433127A3 (en)	1991-10-30
HUT57236A (en)	1991-11-28
FR2655267A1 (fr)	1991-06-07
JPH04108801A (ja)	1992-04-09
CN1062171A (zh)	1992-06-24
CA2031320A1 (fr)	1991-06-05
EP0433127A2 (de)	1991-06-19
ZA909385B (en)	1992-01-29
AU642933B2 (en)	1993-11-04
KR910011878A (ko)	1991-08-07
AP9000229A0 (en)	1991-01-31
FR2655267B1 (fr)	1992-04-03
US5182378A (en)	1993-01-26
PT96060A (pt)	1991-09-30
AU6766490A (en)	1991-06-06
OA09899A (fr)	1994-09-15
IE904342A1 (en)	1991-06-05

Publication	Publication Date	Title
US4397838A (en)	1983-08-09	Preparations of purified bacterial membranal proteoglycans
US9433656B2 (en)	2016-09-06	Picrorhiza kurroa extract for prevention, elimination and treatment of DNA based viruses in humans and in biotech industry
EP0716605A1 (de)	1996-06-19	Blockierung der anlagerung von keimen an menschliche zellen
Yu et al.	2004	Purification and characterization of gypenoside-α-l-rhamnosidase hydrolyzing gypenoside-5 into ginsenoside Rd
IE51590B1 (en)	1987-01-21	Glycoproteins
Horton et al.	1977	Analytical characterization of lipopolysaccharide antigens from seven strains of Pseudomonas aeruginosa
AP281A (en)	1993-08-08	Sulphate derivatives of galactan extracted from klebsiella
EP0030812A2 (de)	1981-06-24	Verfahren zur Herstellung von Interferon-Induktorstoffen und Interferon-Induktoren
US4751218A (en)	1988-06-14	Acylglycan extracts of Klebsiella
EP1002541B1 (de)	2003-05-07	Orale Arzneimittel zur Verbesserung von Aids-Symptomen
EP0213809B1 (de)	1992-03-18	Extrakt von Swertia Japonica Makino und Verfahren zur Herstellung desselben
EP0132981B1 (de)	1989-10-18	Hypotriglyceridemisch aktive Polysaccharide
US9125921B2 (en)	2015-09-08	Picrorhiza extract for prevention, elimination and treatment of infection diseases
EP0286869A1 (de)	1988-10-19	Verfahren zur Herstellung von Zellwandkomponenten aus Halobakterien und deren Verwendung als Arzneimittel
Nakagomi et al.	1987	Inhibition by aloenin and barbaloin of histamine release from rat peritoneal mast cells
CA2235177C (en)	2008-03-11	New exocellular polysaccharide produced by streptococcus thermophilus
JPH0345601A (ja)	1991-02-27	クレブシエラ属から抽出されたガラクタン、その製造方法及び薬剤としての使用
DE2658563C2 (de)	1993-07-15
DE3686607T2 (de)	1993-01-21	Hypocholesttrinaemisch und/oder hypotriglyceridaemisch aktive rns-fraktionen.
Hoffmann et al.	2015	Novel sulfated phosphoglycolipids from Natronomonas moolapensis
JPH0491030A (ja)	1992-03-24	サンショウ由来抗変異原性作用剤
JPH10287583A (ja)	1998-10-27	エイズ症状改善作用を有する経口投与剤
JPH0816119B2 (ja)	1996-02-21	蛋白多糖体ｋｖ−０７１及びそれを有効成分とするヒトロタウイルス感染症予防剤
JPS63233921A (ja)	1988-09-29	抗腫瘍活性物質及びその製造法
JPS62246591A (ja)	1987-10-27	ギムネマ・シルベスタ有効成分抽出物の製造法